Business
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 m
About this update from Immucell Corporation
[{"type":"image","alt":"ImmuCell Corporation","displaySize":"","headline":null,"caption":"ImmuCell Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7ckduXNsI_qLHBNY2yY.og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc","width":300,"height":36}},"lazy":false},{"type":"text","content":"PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025.","length":396,"tagName":"p"},{"type":"text","content":"Product Sales Highlights:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 million compared to the first quarter of 2024.","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"During the six-month period ended March 31, 2025, product sales increased by 28% to approximately $15.8 million compared to the six-month period ended March 31, 2024.","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"During the twelve-month period ended March 31, 2025, product sales increased by 28% to approximately $27.3 million compared to the twelve-month period ended March 31, 2024. ","length":172,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":470,"olType":false},{"type":"text","content":"Preliminary, unaudited product sales for the first quarter of 2025 were first reported on April 8, 2025. There are no changes to those figures.","length":143,"tagName":"p"},{"type":"text","content":"Management’s Discussion:","length":24,"tagName":"p"},{"type":"text","content":"“Product sales during the first quarter of 2025 of $8.1 million set a record high for us, beating the previous record set during the fourth quarter of 2024,” commented Michael F. Brigham, President and CEO of ImmuCell. “We also set a quarterly record for net income, which...